Basis for Androgen Receptor Antagonist Resistance in CRPC

$292,751P01FY2013CANIH

Beth Israel Deaconess Medical Center, Boston MA

Investigators

Linked publications, trials & patents

Paper 39560645 Paper 39117800 Paper 39103353 Paper 39071291 Paper 38894678 Paper 38877132 Paper 38760413 Paper 38687617 Paper 38585965 Paper 38551513 Paper 38450798 Paper 38345532 Paper 38335292 Paper 38197680 Paper 38196594 Paper 38182874 Paper 37999103 Paper 37850574 Paper 37796107 Paper 37725435 Paper 37663929 Paper 37440313 Paper 37400528 Paper 37352376 Paper 37347559 Paper 37065756 Paper 36877164 Paper 36821396 Paper 36779357 Paper 36650259 Paper 36622276 Paper 36621991 Paper 36511483 Paper 36413141 Paper 36399432 Paper 36374194 Paper 36344556 Paper 36337169 Paper 36309102 Paper 36112348 Paper 36109521 Paper 35943799 Paper 35695870 Paper 35603787 Paper 35552660 Paper 35523889 Paper 35468964 Paper 35201849 Paper 35188070 Paper 35131873 Paper 35121110 Paper 35103972 Paper 35031563 Paper 34911936 Paper 34907080 Paper 34877933 Paper 34599169 Paper 34496240 Paper 34493733 Paper 34431104 Paper 34407973 Paper 34312180 Paper 34256096 Paper 34172788 Paper 33998604 Paper 33932081 Paper 33849963 Paper 33785741 Paper 33755225 Paper 33724955 Paper 33658518 Paper 33556543 Paper 33483372 Paper 33481853 Paper 33199493 Paper 33086052 Paper 32989253 Paper 32962734 Paper 32934023 Paper 32868907 Paper 32690948 Paper 32484436 Paper 32478682 Paper 32461304 Paper 32460015 Paper 32276929 Paper 32068909 Paper 32054790 Paper 31932493 Paper 31894239 Paper 31759992 Paper 31676563 Paper 31672619 Paper 31503550 Paper 31444154 Paper 31409897 Paper 31376206 Paper 31366581 Paper 31273194 Patent 9671405

Abstract

.. Currently available AR antagonists such as bicalutamide have limited activity in castration-resistant prostate cancer (CRPC). Mechanistic studies have shown that the bicalutamide liganded AR can accumulate in the nucleus and bind to chromatin, but that it does not effectively recruit coactivator proteins and instead can recruit the corepressor proteins NCoR and SMRT. This ability to mediate chromatin binding may be an

View original record on NIH RePORTER →